A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
<p><strong>Background:</strong> Isocitrate dehydrogenase-1 mutations (IDH1+) result in production of the oncometabolite 2-hydroxyglutarate, arrested differentiation, and increased dependence on the anti-apoptotic protein BCL-2, enhancing susceptibility to the BCL-2 inhibitor veneto...
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Fformat: | Journal article |
| Iaith: | English |
| Cyhoeddwyd: |
American Society of Clinical Oncology
2022
|